| scholarly article | Q13442814 |
| P50 | author | Paul S. Aisen | Q30299891 |
| Thomas J Montine | Q67207389 | ||
| Douglas R. Galasko | Q67228424 | ||
| Elaine Peskind | Q92094304 | ||
| Gregory A Jicha | Q92594727 | ||
| P2093 | author name string | Christopher M Clark | |
| John M Ringman | |||
| Joseph F Quinn | |||
| Carl Cotman | |||
| Ronald G Thomas | |||
| Alzheimer’s Disease Cooperative Study | |||
| Barbara Cottrell | |||
| P2860 | cites work | Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo | Q24603976 |
| “Mini-mental state” | Q25938989 | ||
| Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease | Q27860795 | ||
| Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality | Q28292632 | ||
| Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III. | Q30494108 | ||
| The role of biomarkers in clinical trials for Alzheimer disease | Q31032781 | ||
| Biomarkers of oxidative damage and inflammation in Alzheimer's disease | Q33771834 | ||
| MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial | Q33960122 | ||
| Evaluation of coenzyme Q as an antioxidant strategy for Alzheimer's disease | Q34098304 | ||
| Cerebrospinal fluid and plasma biomarkers in Alzheimer disease | Q34098866 | ||
| Vitamin E and donepezil for the treatment of mild cognitive impairment | Q34411313 | ||
| Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline | Q34528059 | ||
| Impact of antioxidants, zinc, and copper on cognition in the elderly: a randomized, controlled trial | Q34654493 | ||
| Lipid peroxidation in aging brain and Alzheimer's disease | Q34809194 | ||
| Oxidative stress in brain aging. Implications for therapeutics of neurodegenerative diseases | Q34976991 | ||
| The role of nutrition in Alzheimer's disease: epidemiological evidence | Q34999138 | ||
| Lipoic acid as a potential therapy for chronic diseases associated with oxidative stress | Q35768380 | ||
| Mitochondrial dysfunction and oxidative damage in Alzheimer's and Parkinson's diseases and coenzyme Q10 as a potential treatment | Q35891905 | ||
| Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects | Q36225925 | ||
| Oxidative damage in mild cognitive impairment and early Alzheimer's disease | Q36825753 | ||
| Antioxidants and cognitive training interact to affect oxidative stress and memory in APP/PSEN1 mice | Q37061262 | ||
| Chronic antioxidant therapy reduces oxidative stress in a mouse model of Alzheimer's disease | Q37174350 | ||
| The canine (dog) model of human aging and disease: dietary, environmental and immunotherapy approaches. | Q37354760 | ||
| Antioxidants and aging: NMR-based evidence of improved skeletal muscle perfusion and energetics | Q37430894 | ||
| Alpha-lipoic acid as a new treatment option for Alzheimer's disease--a 48 months follow-up analysis. | Q42636363 | ||
| Idebenone treatment fails to slow cognitive decline in Alzheimer's disease | Q44685031 | ||
| Galantamine maintains ability to perform activities of daily living in patients with Alzheimer's disease | Q44946319 | ||
| Coenzyme Q10 attenuates beta-amyloid pathology in the aged transgenic mice with Alzheimer presenilin 1 mutation | Q46818462 | ||
| Chronic dietary alpha-lipoic acid reduces deficits in hippocampal memory of aged Tg2576 mice | Q46920845 | ||
| Early vitamin E supplementation in young but not aged mice reduces Abeta levels and amyloid deposition in a transgenic model of Alzheimer's disease | Q48125251 | ||
| Increased CSF F2-isoprostane concentration in probable AD. | Q48279805 | ||
| A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study | Q48725577 | ||
| Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke | Q49117210 | ||
| Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. | Q51576488 | ||
| Plaque-derived oxidative stress mediates distorted neurite trajectories in the Alzheimer mouse model. | Q53282362 | ||
| Longitudinal stability of CSF biomarkers in Alzheimer's disease. | Q53286684 | ||
| Biochemical markers in persons with preclinical familial Alzheimer disease. | Q53294586 | ||
| P433 | issue | 7 | |
| P921 | main subject | Alzheimer's disease | Q11081 |
| biomarker | Q864574 | ||
| cerebrospinal fluid | Q54196 | ||
| P304 | page(s) | 836-841 | |
| P577 | publication date | 2012-07-01 | |
| P1433 | published in | Archives of Neurology | Q15766672 |
| P1476 | title | Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures | |
| P478 | volume | 69 |
| Q64099551 | A novel synbiotic delays Alzheimer's disease onset via combinatorial gut-brain-axis signaling in Drosophila melanogaster |
| Q37456775 | A randomized placebo-controlled pilot trial of omega-3 fatty acids and alpha lipoic acid in Alzheimer's disease |
| Q38430295 | AOD: the antioxidant protein database |
| Q28389419 | Adaptive cellular stress pathways as therapeutic targets of dietary phytochemicals: focus on the nervous system |
| Q91640915 | Adjuvant Therapies in Diabetic Retinopathy as an Early Approach to Delay Its Progression: The Importance of Oxidative Stress and Inflammation |
| Q64814763 | Alpha-lipoic acid in the treatment of psychiatric and neurological disorders: a systematic review |
| Q48550641 | Angiotensin Converting Enzyme Inhibitors Ameliorate Brain Inflammation Associated with Microglial Activation: Possible Implications for Alzheimer's Disease |
| Q36271462 | Antioxidant peroxiredoxin 6 protein rescues toxicity due to oxidative stress and cellular hypoxia in vitro, and attenuates prion-related pathology in vivo |
| Q33570528 | Ascorbic acid and the brain: rationale for the use against cognitive decline |
| Q39187895 | Association of Antioxidant Supplement Use and Dementia in the Prevention of Alzheimer's Disease by Vitamin E and Selenium Trial (PREADViSE). |
| Q38620338 | Benefits and risks of add-on therapies for Alzheimer's disease |
| Q56990860 | Biology-oriented development of novel lipophilic antioxidants with neuroprotective activity |
| Q89683589 | Central and Peripheral Metabolic Defects Contribute to the Pathogenesis of Alzheimer's Disease: Targeting Mitochondria for Diagnosis and Prevention |
| Q38289739 | Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases |
| Q91981937 | CoQ10 and Aging |
| Q49829630 | Coenzyme Q10 Supplementation in Aging and Disease. |
| Q30401821 | Coenzyme Q10 and α-tocopherol reversed age-associated functional impairments in mice. |
| Q33956936 | Coenzyme q10 therapy |
| Q34685307 | Current experience in testing mitochondrial nutrients in disorders featuring oxidative stress and mitochondrial dysfunction: rational design of chemoprevention trials. |
| Q46287807 | Deuterium-reinforced polyunsaturated fatty acids improve cognition in a mouse model of sporadic Alzheimer's disease |
| Q92193185 | Diet Associated with Inflammation and Alzheimer's Disease |
| Q34037640 | Diet, cognition, and Alzheimer's disease: food for thought |
| Q36874654 | Dietary Alpha-Lipoic Acid Alters Piglet Neurodevelopment |
| Q99711765 | Dietary interventions and cognition of Alzheimer's disease patients: a systematic review of randomized controlled trial |
| Q39400501 | Does Vitamin C Influence Neurodegenerative Diseases and Psychiatric Disorders? |
| Q43618382 | Dual-energy precursor and nuclear erythroid-related factor 2 activator treatment additively improve redox glutathione levels and neuron survival in aging and Alzheimer mouse neurons upstream of reactive oxygen species |
| Q38550867 | Effect of Vitamin Intake on Cognitive Decline in Older Adults: Evaluation of the Evidence |
| Q50746664 | Effect of one-year vitamin C- and E-supplementation on cerebrospinal fluid oxidation parameters and clinical course in Alzheimer's disease. |
| Q41018036 | Effect of pomegranate extracts on brain antioxidant markers and cholinesterase activity in high fat-high fructose diet induced obesity in rat model |
| Q50248146 | Effects of an antioxidant beverage on biomarkers of oxidative stress in Alzheimer's patients |
| Q38742951 | Epigenetic Treatment of Neurodegenerative Disorders: Alzheimer and Parkinson Diseases |
| Q34551041 | Ginkgo biloba extract and long-term cognitive decline: a 20-year follow-up population-based study |
| Q34458474 | Glial lipid droplets and ROS induced by mitochondrial defects promote neurodegeneration |
| Q35034114 | How to design nutritional intervention trials to slow cognitive decline in apparently healthy populations and apply for efficacy claims: a statement from the International Academy on Nutrition and Aging Task Force. |
| Q39164694 | Hydrogen-rich water achieves cytoprotection from oxidative stress injury in human gingival fibroblasts in culture or 3D-tissue equivalents, and wound-healing promotion, together with ROS-scavenging and relief from glutathione diminishment |
| Q34160762 | Influence of lifestyle modifications on age-related free radical injury to brain |
| Q34123865 | Inhibition of AMP-activated protein kinase signaling alleviates impairments in hippocampal synaptic plasticity induced by amyloid β. |
| Q38056497 | Inhibition of GTRAP3-18 may increase neuroprotective glutathione (GSH) synthesis |
| Q89542342 | Insulin resistance and impaired lipid metabolism as a potential link between diabetes and Alzheimer's disease |
| Q91675640 | Is Alzheimer's Disease Risk Modifiable? |
| Q39387457 | Is there a causal link between inflammation and dementia? |
| Q92192403 | Leveraging the interplay of nanotechnology and neuroscience: Designing new avenues for treating central nervous system disorders |
| Q39140990 | Lipid peroxidation in cell death |
| Q38191024 | Lipidomics of Alzheimer's disease |
| Q36205039 | Low-density lipoprotein receptor-related protein 1: a physiological Aβ homeostatic mechanism with multiple therapeutic opportunities |
| Q37361122 | Lymphocyte mitochondria: toward identification of peripheral biomarkers in the progression of Alzheimer disease |
| Q47280890 | Markers of oxidative damage to lipids, nucleic acids and proteins and antioxidant enzymes activities in Alzheimer's disease brain: A meta-analysis in human pathological specimens. |
| Q35752353 | Mechanism of Oxidative Stress and Synapse Dysfunction in the Pathogenesis of Alzheimer's Disease: Understanding the Therapeutics Strategies |
| Q90114589 | Mitochondria Targeted Therapeutics for Alzheimer's Disease: The Good. The Bad. The Potential |
| Q90049866 | Mitochondria as Potential Targets in Alzheimer Disease Therapy: An Update |
| Q38678059 | Mitochondria-Targeted Antioxidants for the Treatment of Cardiovascular Disorders |
| Q52621890 | Mitochondrial Agents for Bipolar Disorder. |
| Q33608218 | Mitochondrial DNA damage in a mouse model of Alzheimer's disease decreases amyloid beta plaque formation |
| Q43198180 | Mitochondrial Dysfunction and Chronic Disease: Treatment With Natural Supplements |
| Q26767051 | Mitochondrial Dysfunction in Cancer and Neurodegenerative Diseases: Spotlight on Fatty Acid Oxidation and Lipoperoxidation Products |
| Q26800963 | Molecular Mechanisms and Therapeutic Effects of (-)-Epicatechin and Other Polyphenols in Cancer, Inflammation, Diabetes, and Neurodegeneration |
| Q42701390 | Molecular interactions with redox sites and salt bridges modulate the anti-aggregatory effect of flavonoid, tannin and cardenolide moieties against amyloid-beta (1-42) in silico |
| Q26744105 | Multi-Target Directed Donepezil-Like Ligands for Alzheimer's Disease |
| Q64880531 | Natural Compounds for Alzheimer's Disease Therapy: A Systematic Review of Preclinical and Clinical Studies. |
| Q34116168 | Neuronal injury from cardiac arrest: aging years in minutes. |
| Q97882922 | Neuroprotection Against Oxidative Stress: Phytochemicals Targeting TrkB Signaling and the Nrf2-ARE Antioxidant System |
| Q88585418 | Neuroprotective evidence of alpha-lipoic acid and desvenlafaxine on memory deficit in a neuroendocrine model of depression |
| Q37489112 | Normal Vitamin Levels and Nutritional Indices in Alzheimer's Disease Patients with Mild Cognitive Impairment or Dementia with Normal Body Mass Indexes |
| Q91246348 | Nutrients in Alzheimer's Disease: The Interaction of Diet, Drugs and Disease |
| Q38243598 | Nutrition and brain aging: how can we move ahead? |
| Q34369234 | Nutrition and prevention of Alzheimer's dementia |
| Q22241959 | Nutrition and the risk of Alzheimer's disease |
| Q37244943 | Nutritional and safety outcomes from an open-label micronutrient intervention for pediatric bipolar spectrum disorders |
| Q38537727 | Oral and enteral nutrition in dementia: an overview |
| Q36632830 | Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study |
| Q52595131 | Oxidant/Antioxidant Imbalance in Alzheimer's Disease: Therapeutic and Diagnostic Prospects. |
| Q38330385 | Oxidative Stress in Alzheimer's Disease: Should We Keep Trying Antioxidant Therapies? |
| Q26801239 | Oxidative Stress in Neurodegenerative Diseases |
| Q33614523 | Oxidative Stress, Synaptic Dysfunction, and Alzheimer's Disease |
| Q38121221 | Oxidative stress in Alzheimer's disease: Primary villain or physiological by-product? |
| Q37616153 | Oxidative stress in Alzheimer's disease: why did antioxidant therapy fail? |
| Q42123491 | Oxidative stress signaling to chromatin in health and disease. |
| Q36599276 | Plasma methionine sulfoxide in persons with familial Alzheimer's disease mutations |
| Q36553760 | Presenilin-1 adopts pathogenic conformation in normal aging and in sporadic Alzheimer's disease |
| Q34675868 | Progress in Alzheimer's disease research in the last year |
| Q36421954 | Protein S-Nitrosylation as a Therapeutic Target for Neurodegenerative Diseases |
| Q30779251 | Rationale and clinical data supporting nutritional intervention in Alzheimer's disease |
| Q33556068 | Recent Progress in Alzheimer's Disease Research, Part 3: Diagnosis and Treatment |
| Q38802429 | Rhodiola rosea L. and Alzheimer's Disease: From Farm to Pharmacy. |
| Q61801376 | Rosenroot (): Potential Applications in Aging-related Diseases |
| Q92674430 | Souvenaid in the management of mild cognitive impairment: an expert consensus opinion |
| Q55279804 | Strategies to decrease oxidative stress biomarker levels in human medical conditions: A meta-analysis on 8-iso-prostaglandin F2α. |
| Q38253060 | Strategy to reduce free radical species in Alzheimer's disease: an update of selected antioxidants. |
| Q38571878 | Streptozotocin Intracerebroventricular-Induced Neurotoxicity and Brain Insulin Resistance: a Therapeutic Intervention for Treatment of Sporadic Alzheimer's Disease (sAD)-Like Pathology |
| Q58697995 | Suppression of Presymptomatic Oxidative Stress and Inflammation in Neurodegeneration by Grape-Derived Polyphenols |
| Q47689697 | Tau-based therapies in neurodegeneration: opportunities and challenges |
| Q35800000 | The Ambiguous Relationship of Oxidative Stress, Tau Hyperphosphorylation, and Autophagy Dysfunction in Alzheimer's Disease |
| Q64256652 | The Effectiveness of Vitamin E Treatment in Alzheimer's Disease |
| Q41111155 | The Essentials of a Global Index for Cognitive Function |
| Q28074531 | The Impact of Vitamin E and Other Fat-Soluble Vitamins on Alzheimer´s Disease |
| Q90192923 | The Paradox of Coenzyme Q10 in Aging |
| Q26771758 | The Role of Oxidative Stress in Neurodegenerative Diseases |
| Q37701328 | The basic biology of redoxosomes in cytokine-mediated signal transduction and implications for disease-specific therapies |
| Q44656818 | The effect of antioxidant vitamins E and C on cognitive performance of the elderly with mild cognitive impairment in Isfahan, Iran: a double-blind, randomized, placebo-controlled trial |
| Q38841508 | The entangled ER-mitochondrial axis as a potential therapeutic strategy in neurodegeneration: A tangled duo unchained |
| Q37514284 | The paradox of overnutrition in aging and cognition |
| Q38672062 | The use of cerebrospinal fluid biomarkers to measure change in neurodegeneration in Alzheimer's disease clinical trials |
| Q62863202 | Therapeutic potential of vitamin E and its derivatives in traumatic brain injury-associated dementia |
| Q55266361 | Tocotrienol-Rich Fraction of Palm Oil Improves Behavioral Impairments and Regulates Metabolic Pathways in AβPP/PS1 Mice. |
| Q61450425 | Translating the biology of aging into novel therapeutics for Alzheimer disease |
| Q38149130 | Treatment of Alzheimer's Disease: Current Management and Experimental Therapeutics |
| Q36337525 | Upcoming candidate cerebrospinal fluid biomarkers of Alzheimer's disease |
| Q42368222 | Vitamin C Status and Cognitive Function: A Systematic Review |
| Q39317883 | Vitamin C Supplementation, APOE4 Genotype and Cognitive Functioning in a Rural-Dwelling Cohort. |
| Q35764820 | Vitamin C deficiency in the brain impairs cognition, increases amyloid accumulation and deposition, and oxidative stress in APP/PSEN1 and normally aging mice |
| Q92603728 | Vitamin E and Alzheimer's disease: what do we know so far? |
| Q56092262 | Vitamin E for Alzheimer's dementia and mild cognitive impairment |
| Q34550138 | Vitamin E for Alzheimer's dementia and mild cognitive impairment. |
| Q36963311 | Vitamin E in aging persons with Down syndrome: A randomized, placebo-controlled clinical trial |
| Q38866263 | Vitamin E: Curse or Benefit in Alzheimer's Disease? A Systematic Investigation of the Impact of α-, γ- and δ-Tocopherol on Aß Generation and Degradation in Neuroblastoma Cells. |
| Q38034060 | What have we learned from the streptozotocin-induced animal model of sporadic Alzheimer's disease, about the therapeutic strategies in Alzheimer's research |
| Q46252229 | α-Lipoic acid, functional fatty acid, as a novel therapeutic alternative for central nervous system diseases: A review |
Search more.